Esophageal Squamous Cell Carcinoma research hub

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.

ETCABio - Evaluation of Skin Tests in Biotherapy Allergies

This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.

MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO